Finance

Therion Completes $36.5 Million Private Financing For Development

Published in Vaccine Weekly, November 21st, 2001

Providing new resources to advance the company's clinical development programs, Therion Biologics has closed a $36.5 million private financing with leading venture investors.

Therion will use the funds to support clinical trials of PROSTVAC-VF, the company's lead cancer vaccine for prostate cancer, and to accelerate the development of its additional therapeutic cancer vaccine programs.

The financing was led by a group including Hans-Werner Hector, one of the founders of the German software company SAP. In addition to Hector's investment in Therion, he has established one of the largest private charitable foundations in Germany, through which he...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2001-11-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry